Demegen, Inc. announced today that the Company held its first scientific advisory board meeting.

Demegen's scientific advisory board is comprised of leading scientists from several disciplines. The advisors consult with the Company on R&D strategies and techniques pertaining to Demegen's core platform technologies.

In announcing the advisory board, Dr. Jesse M. Jaynes, vice president of research for Demegen, said: "The diversity of the board may appear unusual, but we have chosen the members carefully. We wanted people who not only understood our core strength of molecular design, but also the requirements of practical product commercialization. We expect this unique group will both challenge and assist us.''

The distinguished members of Demegen's scientific advisory board are as follows:

Paul L. Kornblith, M.D. serves as president and founder of Precision Therapeutics, Inc. in
Pittsburgh and as an adjunct professor in the School of Health and Rehabilitation Sciences at the
University of Pittsburgh. He is editor-in-chief of the Journal of Neuro-Oncology and sits on the
editorial boards of five other cancer and neurosurgical journals. Dr. Kornblith's background also
includes work as vice chairman and professor of neurosurgery and co-director of the University of
Pittsburgh Brain Tumor Center as well as chief of the surgical neurology branch, NINCDS, at the
National Institutes of Health.

Roger A. Laine, Ph.D. is professor of biochemistry and molecular biology and director of the
LSU Mass Spectrometry Facility at Louisiana State University. Dr. Laine is also president and
founder of Anomeric, Inc., a company that develops microbial diagnostic products. He was
previously the scientific founder of Glycomed, which developed cancer therapeutics from complex
carbohydrates and is now a part of Ligand Pharmaceuticals, Inc.

Wayne F. Tompkins, Ph.D. is professor of microbiology, pathology, and parasitology as well as
immunology programs coordinator at North Carolina State University in Raleigh. Dr. Tompkins is
recognized nationally for his work as co-developer of the Feline Immunodeficiency Virus (FIV)
model, which is an accepted animal model for testing potential HIV therapeutics for humans. He
has published extensively in the fields of virology and immunology.

Paul S. Zorner, Ph.D. is senior scientist of the Global Industrial Biotechnology Platform at The
Dow Chemical Co. and was formerly vice president of product development at Mycogen Corp.
that was acquired by Dow. Dr. Zorner holds over 20 U.S. patents. He also serves as chairman of
the strategic planning committee, member of the publication board, and member of the sustainable agricultural committee at the Weed Science Society of America.

Demegen, Inc. is a biopharmaceutical firm that designs novel synthetic peptides and proteins. The Company is currently conducting preclinical development of its patented compounds for cancers and infectious diseases. Demegen also has patented technologies for disease resistant and nutritionally enhanced commercial crops, and has licensed two broad applications to Dow AgroSciences LLC.

N1760